IL110831A - Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis - Google Patents

Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis

Info

Publication number: IL110831A
Authority: IL; Israel
Prior art keywords: halofuginone; cells; group; growth; inhibition
Prior art date: 1994-08-31

Application number

IL11083194A

Other languages

English (en)

Other versions

IL110831A0 (en

Inventor

Arnon Nagler

Shimon Slavin

Israel Vlodavsky

Mark Pines

Original Assignee

Hadasit Med Res Service

Agriculture Research Organizat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-31

Filing date

1994-08-31

Publication date

1998-12-27

1994-08-31 Application filed by Hadasit Med Res Service, Agriculture Research Organizat filed Critical Hadasit Med Res Service

1994-08-31 Priority to IL11083194A priority Critical patent/IL110831A/en

1994-11-11 Publication of IL110831A0 publication Critical patent/IL110831A0/xx

1995-08-29 Priority to CN95195353A priority patent/CN1108797C/zh

1995-08-29 Priority to CA002198875A priority patent/CA2198875C/en

1995-08-29 Priority to AT95933731T priority patent/ATE197401T1/de

1995-08-29 Priority to PCT/US1995/011186 priority patent/WO1996006616A1/en

1995-08-29 Priority to EP95933731A priority patent/EP0787000B1/de

1995-08-29 Priority to DE69519385T priority patent/DE69519385T2/de

1995-08-29 Priority to JP8508990A priority patent/JPH10513149A/ja

1995-08-29 Priority to AU36268/95A priority patent/AU692307B2/en

1995-08-29 Priority to US08/722,046 priority patent/US5891879A/en

1996-08-30 Priority to IL11916296A priority patent/IL119162A/xx

1998-12-27 Publication of IL110831A publication Critical patent/IL110831A/en

Links

210000000329 smooth muscle myocyte Anatomy 0.000 description 29
210000004027 cell Anatomy 0.000 description 28
LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 25
229950010152 halofuginone Drugs 0.000 description 25
230000012010 growth Effects 0.000 description 13
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 12
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 12
150000001875 compounds Chemical class 0.000 description 10
230000002792 vascular Effects 0.000 description 10
210000002950 fibroblast Anatomy 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
230000001028 anti-proliverative effect Effects 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
238000010348 incorporation Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
210000003556 vascular endothelial cell Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
208000037803 restenosis Diseases 0.000 description 6
229940104230 thymidine Drugs 0.000 description 6
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
210000002744 extracellular matrix Anatomy 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
238000002399 angioplasty Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000006820 DNA synthesis Effects 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
108090000190 Thrombin Proteins 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
-1 hydroxy, acetoxy Chemical group 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000000923 atherogenic effect Effects 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
229960000907 methylthioninium chloride Drugs 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
229960005314 suramin Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
LVASCWIMLIKXLA-UHFFFAOYSA-N 7-Bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]-3,4-dihydroquinazolin-4-one Chemical compound OC1CCCNC1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
208000003495 Coccidiosis Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100024025 Heparanase Human genes 0.000 description 1
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
206010023076 Isosporiasis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
208000001117 Theileriasis Diseases 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000009668 clonal growth Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
108010037536 heparanase Proteins 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940028435 intralipid Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL11083194A 1994-08-31 1994-08-31 Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis IL110831A (en)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
IL11083194A IL110831A (en)	1994-08-31	1994-08-31	Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US08/722,046 US5891879A (en)	1994-08-31	1995-08-29	Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
PCT/US1995/011186 WO1996006616A1 (en)	1994-08-31	1995-08-29	Quinazolinone pharmaceuticals and use thereof
CA002198875A CA2198875C (en)	1994-08-31	1995-08-29	Quinazolinone pharmaceuticals and use thereof
AT95933731T ATE197401T1 (de)	1994-08-31	1995-08-29	Chinazolinon-arzneimittel sowie deren verwendung
CN95195353A CN1108797C (zh)	1994-08-31	1995-08-29	喹唑酮药物及其应用
EP95933731A EP0787000B1 (de)	1994-08-31	1995-08-29	Chinazolinon-arzneimittel sowie deren verwendung
DE69519385T DE69519385T2 (de)	1994-08-31	1995-08-29	Chinazolinon-arzneimittel sowie deren verwendung
JP8508990A JPH10513149A (ja)	1994-08-31	1995-08-29	キナゾリノン医薬品及びその利用
AU36268/95A AU692307B2 (en)	1994-08-31	1995-08-29	Quinazolinone pharmaceuticals and use thereof
IL11916296A IL119162A (en)	1994-08-31	1996-08-30	Intracoronary stents containing quinazolinone derivatives

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL11083194A IL110831A (en)	1994-08-31	1994-08-31	Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis

Publications (2)

Publication Number	Publication Date
IL110831A0 IL110831A0 (en)	1994-11-11
IL110831A true IL110831A (en)	1998-12-27

Family

ID=11066514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11083194A IL110831A (en)	1994-08-31	1994-08-31	Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis

Country Status (8)

Country	Link
EP (1)	EP0787000B1 (de)
JP (1)	JPH10513149A (de)
CN (1)	CN1108797C (de)
AT (1)	ATE197401T1 (de)
AU (1)	AU692307B2 (de)
DE (1)	DE69519385T2 (de)
IL (1)	IL110831A (de)
WO (1)	WO1996006616A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL114951A (en) *	1995-08-15	1999-08-17	Hadasit Med Res Service	Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
JP2001500040A (ja) *	1996-08-30	2001-01-09	イスラエル国	キナゾリノン誘導体を含有する冠状動脈内ステント
US6211188B1 (en) *	1997-02-11	2001-04-03	Hadasit Medical Research Services And Development Company Ltd	Treatment of skin disorders
US6028075A (en)	1997-02-11	2000-02-22	Pines; Mark	Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US6562829B1 (en)	1997-05-23	2003-05-13	Hadasit Medical Research Services & Development Co., Ltd.	Treatment of hepatic cirrhosis
US6159488A (en) *	1997-08-14	2000-12-12	Agricultural Research Org. Ministry Of Agriculture (Gov.)	Intracoronary stents containing quinazolinone derivatives
WO2000009070A2 (en) *	1998-08-13	2000-02-24	Hadasit Medical Research Services And Development Company Ltd.	Inhibition of pathogenic processes related to tissue trauma
EP1162974A1 (de) *	1999-03-19	2001-12-19	Parker Hughes Institute	Quinazoline formulierungen und therapeutische verwendung
US7064114B2 (en)	1999-03-19	2006-06-20	Parker Hughes Institute	Gel-microemulsion formulations
AU764435B2 (en) *	1999-09-09	2003-08-21	Hadasit Medical Research Services & Development Company Ltd	Promotion of wound healing
US7230000B1 (en)	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
WO2003043995A1 (en)	2001-11-20	2003-05-30	Cytokinetics, Inc.	Process for the racemization of chiral quinazolinones
JP2005529076A (ja)	2002-02-15	2005-09-29	サイトキネティクス・インコーポレーテッド	キナゾリノンの合成
EP1553931A4 (de)	2002-05-09	2006-08-30	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
RU2004135554A (ru)	2002-05-09	2006-01-20	Цитокинетикс, Инк. (Us)	Пиримидиноны, композиции на их основе и способы их использования
EP1513820A4 (de)	2002-05-23	2006-09-13	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
CA2489367A1 (en)	2002-06-14	2003-12-24	Cytokinetics, Inc.	Compounds, compositions, and methods
EP1537089A4 (de)	2002-07-23	2008-04-16	Cytokinetics Inc	Verbindungen, zusammenstellungen und verfahren
WO2004034972A2 (en)	2002-09-30	2004-04-29	Cytokinetics, Inc.	Compounds, compositions, and methods
EP1692112A4 (de)	2003-12-08	2008-09-24	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
KR20100024494A (ko)	2007-06-22	2010-03-05	아르퀼 인코포레이티드	퀴나졸리논 화합물 및 이의 사용 방법
CN114469956B (zh) *	2022-01-29	2023-07-18	中国科学技术大学	常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US26833A (en) *		1860-01-17		Improvement in plows
US3320124A (en) *	1964-07-20	1967-05-16	American Cyanamid Co	Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) *	1979-08-23	1981-03-12	Hoechst Ag, 6000 Frankfurt	Mittel gegen theileriosen und seine verwendung.
DE3703789A1 (de) *	1987-02-07	1988-08-18	Hoechst Ag	Coccidiozide mittel
CA2113229C (en) *	1994-01-11	1999-04-20	Mark Pines	Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof

1994
- 1994-08-31 IL IL11083194A patent/IL110831A/en not_active IP Right Cessation
1995
- 1995-08-29 WO PCT/US1995/011186 patent/WO1996006616A1/en not_active Ceased
- 1995-08-29 EP EP95933731A patent/EP0787000B1/de not_active Expired - Lifetime
- 1995-08-29 AT AT95933731T patent/ATE197401T1/de not_active IP Right Cessation
- 1995-08-29 JP JP8508990A patent/JPH10513149A/ja active Pending
- 1995-08-29 CN CN95195353A patent/CN1108797C/zh not_active Expired - Lifetime
- 1995-08-29 DE DE69519385T patent/DE69519385T2/de not_active Expired - Fee Related
- 1995-08-29 AU AU36268/95A patent/AU692307B2/en not_active Ceased

Also Published As

Publication number	Publication date
EP0787000B1 (de)	2000-11-08
JPH10513149A (ja)	1998-12-15
EP0787000A4 (de)	1997-11-12
AU3626895A (en)	1996-03-22
WO1996006616A1 (en)	1996-03-07
EP0787000A1 (de)	1997-08-06
DE69519385T2 (de)	2001-03-15
CN1108797C (zh)	2003-05-21
IL110831A0 (en)	1994-11-11
AU692307B2 (en)	1998-06-04
CN1163566A (zh)	1997-10-29
DE69519385D1 (de)	2000-12-14
ATE197401T1 (de)	2000-11-11

Legal Events

Date	Code	Title
1999-06-20	FF	Patent granted
2000-06-29	KB	Patent renewed
2001-01-11	KB	Patent renewed
2004-11-10	KB	Patent renewed
2009-09-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
AU692307B2 (en)	1998-06-04	Quinazolinone pharmaceuticals and use thereof
US5891879A (en)	1999-04-06	Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
US6159488A (en)	2000-12-12	Intracoronary stents containing quinazolinone derivatives
WO1996006616A9 (en)	1996-07-11	Quinazolinone pharmaceuticals and use thereof
AU712520B2 (en)	1999-11-11	Intracoronary stents containing quinazolinone derivatives
EA000190B1 (ru)	1998-12-24	Способы подавления миграции сосудистых гладкомышечных клеток
EP0794780B1 (de)	2003-04-23	Chinazolinon enthaltende arzneimittel und verfahren zu deren verwendung
JPH11501911A (ja)	1999-02-16	サイトカイン成長因子の引き起こす疾病の治療
Isaji et al.	2000	Inhibitory effects of tranilast on the proliferation and functions of human pterygium-derived fibroblasts
EP0831807B1 (de)	2005-12-21	Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen
CA2279943C (en)	2004-06-01	Treatment of skin disorders
CA2198875C (en)	2005-11-15	Quinazolinone pharmaceuticals and use thereof
CA2085399A1 (en)	1993-06-17	Method for inhibiting nitric oxide formation
EP1210086B1 (de)	2006-12-06	Verwendung von halofuginone zur behandlung von urethralstriktur
Shirotani et al.	1991	A new type of vasodilator, HA1077, an isoquinoline derivative, inhibits proliferation of bovine vascular smooth muscle cells in culture.
EA001931B1 (ru)	2001-10-22	Применение 2-(3,4-диметоксициннамоил)аминобензойной кислоты для лечения или предотвращения рестеноза
US5998422A (en)	1999-12-07	Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
JP2000191540A (ja)	2000-07-11	再狭窄薬物療法
WO2001068070A2 (en)	2001-09-20	Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
JP2004196791A (ja)	2004-07-15	血管新生阻害物質